How many healthcare workers are exposed to hazardous drugs annually?

Infographic | April 6, 2020

Biomedtracker and Trialtrove have a total of 307 clinical trials for the treatment of COVID-19. 152 initiated trials for the treatment of COVID-19. 155 Trials have been announced but have not yet begun recruitment.

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Infographic | April 16, 2020

Poised to give our readers and advertisers better services in spite of the COVID19 pandemic, Pharmanews–your global health journal has continued to improve on its services in terms of healthcare information dissemination, by keeping readers abreast of latest development in public health, especially on how to stay safe from the novel Coronavirus, as well as expanding our reach to over 250,000 readers per month.

Infographic | June 16, 2022

Use Informa Pharma Intelligence’s marketing and pharma expertise to conduct industry research, produce engaging thought leadership content,

Infographic | March 12, 2022

Pharmaceutical industry and medicine vector infographics with drugs, pills, bottles and packages, text blocks and charts all around

Infographic | May 23, 2021

Pharmacovigilance (PV) is essential to all life science organizations, ensuring that patients' health comes first. Various trends in global healthcare have transformed today’s PV function into a corporate asset that enhances brand value and contributes to new growth opportunities. However, existing safety systems impose a significant cost burden to operate.